If you purchased or acquired securities in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your ...

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...

Merck has partnered with South Korea-based biopharmaceutical company Alteogen (196170.KQ), opens new tab to use a variant of the hyaluronidase family of enzymes, which allows large volume of ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

FRANKFURT, March 6 (Reuters) - Merck KGaA (MRCG.DE), opens new tab ... the family-controlled company added. Healthcare & Pharmaceuticalscategory Trump's FDA nominee tepidly backs role for vaccine ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...